2022
Quarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19
Wells CR, Pandey A, Gokcebel S, Krieger G, Donoghue AM, Singer BH, Moghadas SM, Galvani AP, Townsend JP. Quarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19. PNAS Nexus 2022, 1: pgac100. PMID: 35909795, PMCID: PMC9335027, DOI: 10.1093/pnasnexus/pgac100.Peer-Reviewed Original ResearchSARS-CoV-2Serial testingSerial testing strategyHigh population immunityQuarantine durationBenefits of vaccinationSARS-CoV-2 variantsDisease time courseCOVID-19CoV-2 variantsPublic health toolVaccine boostingThird doseVaccination statusVaccination coveragePopulation immunityCoV-2Health toolsDisease control effortsInfected casesLocal transmissionInfectiousness profileVaccinationTime courseImmunityWaning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.
Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.Peer-Reviewed Original ResearchCOVID-19 vaccinationBlood samplesSystemic treatmentAntibody titersGenitourinary malignanciesSubset of ptsImmune checkpoint inhibitorsBaseline blood samplesLong-term efficacyAdditional blood samplesCOVID-19 vaccineSARS-CoV-2Short-term effectivenessCancer ptsSerologic outcomeCheckpoint inhibitorsGenitourinary cancersMedian ageTherapy cyclesBladder cancerTCR sequencingIgG ELISACoV-2Host immunityVaccination
2021
Longitudinal Assessment of SARS-CoV-2 Anti-Nucleocapsid and anti-Spike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection
El-Khoury JM, Schulz WL, Durant TJS. Longitudinal Assessment of SARS-CoV-2 Anti-Nucleocapsid and anti-Spike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection. The Journal Of Applied Laboratory Medicine 2021, 6: jfab030-. PMID: 33822964, PMCID: PMC8083453, DOI: 10.1093/jalm/jfab030.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionDays post-PCR positivitySARS-CoV-2-positive cohortRBD antibodiesAnti-SARSSerologic assaysSARS-CoV-2 serologic assaysDiagnostic sensitivityElecsys Anti-SARSCoV-2 SResidual clinical samplesAntibody testingRemote historyCoV-2S1-RBDUS populationLongitudinal assessmentInfection statusInfectionDiagnostic aidCohortTime pointsDiscrepant resultsClinical samplesPositivity
2020
Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change
Hwang ES, Balch CM, Balch GC, Feldman SM, Golshan M, Grobmyer SR, Libutti SK, Margenthaler JA, Sasidhar M, Turaga KK, Wong SL, McMasters KM, Tanabe KK. Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. Annals Of Surgical Oncology 2020, 27: 2600-2613. PMID: 32535870, PMCID: PMC7293588, DOI: 10.1245/s10434-020-08673-6.Peer-Reviewed Original ResearchConceptsSurgical oncologistsCancer careCancer patientsCOVID-19 pandemicSurgical oncology careSurgical oncology patientsSARS-CoV-2Health care systemOperable cancerOncology patientsOncologic surgeryOncology careOptimal careEffective vaccineSurgical decisionCoV-2PatientsOncologistsCare systemCareCancer therapyEmpathetic careCOVID-19HospitalProfessional guidelines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply